Clinical Trials
27 trialsCord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Fred Hutchinson Cancer Center
Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia
Roswell Park Cancer Institute
AML Therapy With Irradiated Allogeneic Cells
Rutgers, The State University of New Jersey
Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Stanford University
Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML
Northwestern University
Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Stanford University
Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia
University of Southern California
Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia
The Cleveland Clinic
Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Masonic Cancer Center, University of Minnesota
MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Stanford University
Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission
Fred Hutchinson Cancer Center
Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS
Fred Hutchinson Cancer Center
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Alliance for Clinical Trials in Oncology
Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Roswell Park Cancer Institute
Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Roswell Park Cancer Institute
Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia
National Cancer Institute (NCI)
Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy
Roswell Park Cancer Institute
Gene Expression During Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Choline Magnesium Trisalicylate
Rutgers, The State University of New Jersey
Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
National Cancer Institute (NCI)
Cilengitide in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)